Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Private Placement
PharmAla Closes Private Placement and Concurrent Debt Settlement
Details : Net proceeds will support development of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine) for treating PTSD and social anxiety in autistic adults.
Brand Name : ALA-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 19, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Private Placement
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Private Placement
PharmAla Announces Private Placement and Concurrent Debt Settlement
Details : Net proceeds will support development of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine) for treating PTSD and social anxiety in autistic adults.
Brand Name : ALA-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 10, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Private Placement
Lead Product(s) : ALA-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : University of Sydney
Deal Size : Undisclosed
Deal Type : Agreement
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
Details : The agreement aims for the clinical phase development of ALA-002 which under investigation for the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autistic adults.
Brand Name : ALA-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : ALA-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : University of Sydney
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ALA-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $5.0 million
Deal Type : Private Placement
Details : The Company intends to use the net proceeds to fund phase 2 clinical trials of the Company’s patented ALA series of molecules including, ALA-002, an oral, small molecule drug being developed for the treatment of social anxiety disorder and post-traumat...
Brand Name : ALA-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 12, 2023
Lead Product(s) : ALA-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $5.0 million
Deal Type : Private Placement
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections
Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 03, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Psilocybine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Mindset Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e. pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Mindset Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ALA-002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA
Details : PharmAla’s goal is to bring ALA-002 into the clinic as a treatment for disorders in adults diagnosed with Autism Spectrum Disorder (ASD). ALA-002 was tested not only in general population research, but also in generally accepted autism mouse models.
Brand Name : ALA-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2022
Lead Product(s) : ALA-002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
